Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E CDKN2A R80* |
| Therapy | Dabrafenib + Palbociclib + Trametinib |
| Indication/Tumor Type | rhabdomyosarcoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E CDKN2A R80* | rhabdomyosarcoma | predicted - sensitive | Dabrafenib + Palbociclib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, the combination of Tafinlar (dabrafenib), Ibrance (palbociclib), and Mekinist (trametinib) resulted in a progression-free survival of 9 months in a patient with rhabdomyosarcoma harboring BRAF V600E and CDKN2A R80* (PMID: 33472910). | 33472910 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33472910) | Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. | Full reference... |